Salud financiera de hoja de balance de Cardiff Oncology
Salud financiera controles de criterios 6/6
Cardiff Oncology tiene un patrimonio de los accionistas total de $49.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $62.9M y $13.5M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$57.67m |
| Patrimonio | US$49.39m |
| Total pasivo | US$13.50m |
| Activos totales | US$62.90m |
Actualizaciones recientes sobre salud financiera
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Recent updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($59.3M) de CRDF superan a sus pasivos a corto plazo ($12.5M).
Pasivo a largo plazo: Los activos a corto plazo de CRDF ($59.3M) superan a sus pasivos a largo plazo ($979.0K).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CRDF está libre de deudas.
Reducción de la deuda: CRDF no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CRDF tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CRDF dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 19.5% cada año.